Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer.

[1]  E. Heath,et al.  Angiogenesis inhibitors in the treatment of prostate cancer , 2010, Journal of hematology & oncology.

[2]  Yong Li,et al.  Angiogenesis as a strategic target for prostate cancer therapy , 2010, Medicinal research reviews.

[3]  Y. Bang,et al.  Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma , 2009, Cancer Chemotherapy and Pharmacology.

[4]  G. Wheeler,et al.  Simple vertebrate models for chemical genetics and drug discovery screens: Lessons from zebrafish and Xenopus , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.

[5]  M. Ezhov,et al.  The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients , 2009, Acta cardiologica.

[6]  C. Fong,et al.  Statins, stem cells, and cancer , 2009, Journal of cellular biochemistry.

[7]  Young Suk Park,et al.  Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study , 2009, Cancer Chemotherapy and Pharmacology.

[8]  Tapio Visakorpi,et al.  Statins and prostate cancer prevention: where we are now, and future directions , 2008, Nature Clinical Practice Urology.

[9]  S. Freedland,et al.  Review of recent evidence in support of a role for statins in the prevention of prostate cancer , 2008, Current opinion in urology.

[10]  H. Gbelcová,et al.  Differences in antitumor effects of various statins on human pancreatic cancer , 2008, International journal of cancer.

[11]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[12]  J. Aragon-Ching,et al.  The Role of Angiogenesis Inhibitors in Prostate Cancer , 2008, Cancer journal.

[13]  Audrey White,et al.  Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. , 2007, Cancer research.

[14]  B. Jelaković,et al.  Aristolochic acid and the etiology of endemic (Balkan) nephropathy , 2007, Proceedings of the National Academy of Sciences.

[15]  H. Baier,et al.  A transgene-assisted genetic screen identifies essential regulators of vascular development in vertebrate embryos. , 2007, Developmental biology.

[16]  S. Trudel,et al.  The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan , 2007, Clinical Cancer Research.

[17]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[18]  M. Lohuizen,et al.  Stem Cells and Cancer The Polycomb Connection , 2004, Cell.

[19]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[20]  R Scott Lokey,et al.  Forward chemical genetics: progress and obstacles on the path to a new pharmacopoeia. , 2003, Current opinion in chemical biology.

[21]  A. Zeiher,et al.  Double-Edged Role of Statins in Angiogenesis Signaling , 2002, Circulation research.

[22]  C. Heeschen,et al.  Statins Have Biphasic Effects on Angiogenesis , 2002, Circulation.

[23]  B. Weinstein,et al.  The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. , 2001, Developmental biology.

[24]  I. Shiojima,et al.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. , 2000, Nature Medicine.

[25]  J. Casida,et al.  Anticancer action of cubé insecticide: correlation for rotenoid constituents between inhibition of NADH:ubiquinone oxidoreductase and induced ornithine decarboxylase activities. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[27]  J. Folkman,et al.  Protamine is an inhibitor of angiogenesis , 1982, Nature.

[28]  W. Hong,et al.  Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia‐inducible factor‐1 alpha , 2008, International journal of cancer.

[29]  J. Folkman.  Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[30]  L. Zon,et al.  In vivo drug discovery in the zebrafish , 2005, Nature Reviews Drug Discovery.

[31]  G. Serbedzija,et al.  Zebrafish angiogenesis: A new model for drug screening , 2004, Angiogenesis.

[32]  Emmett T. Cunningham,et al.  VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION CLINICAL TRIAL GROUP. PEGAPTANIB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2004 .